1. Non-genotoxic carcinogenesis
Expected outcome: proven reliable role of early biomarkers in the prediction of cancer development.
2. Expert systems for in silico toxicity prediction
Expected outcome: in silico prediction and expert systems for secondary pharmacology prediction and for pure chemistry-related toxicity.
3. Qualification of translational safety biomarkers
Expected outcome: new specific and sensitive safety biomarkers and their respective assays for human sample for improved predictivity between non-clinical and early clinical studies.
4. Strengthening the monitoring of the benefit/risk of medicines
Expected outcome: new methodologies in pharmacovigilance and pharmacoepidemiology
5. Islet cell research
Expected outcome: better understanding of β-cell proliferation, differentiation and apoptosis permitting the identification of approaches to preserve ß cell function aiding the development of preventive and curative treatments for diabetes types 1 and 2.
6. Surrogate markers for vascular endpoints
Expected outcome: biomarkers/surrogate endpoints for micro- and macrovascular hard endpoints in diabetes clinical research and new in vitro or in silico tools to test novel therapies.
7. Pain research
Expected outcome: improved understanding of the pathways and mechanisms mediating different kinds of pain, and markers for patient stratification and quantitative pain assessment for efficient testing of new analgesics.
8. New tools for the development of novel therapies in psychiatric disorders
Expected outcome: blood/CSF markers, imaging and/or electrophysiological measures suitable for clinical assessments to be used for preclinical models with sensitive pharmacodynamic markers that are closely linked with psychiatric disorders
9. Neurodegenerative disorders
Expected outcome: translatable animal and human volunteer models for better prediction of clinical efficacy of new therapies in patients with Alzheimer´s disease, Parkinson´s disease and multiple sclerosis.
10. Understanding severe asthma
Expected outcome: a large longitudinal patient cohort enabling validation of novel biomarkers and development of diagnostic criteria for mechanistic and therapeutic trials.
11. COPD patient recorded outcomes
Expected outcome: a framework for better understanding of patients´ experience of chronic obstructive pulmonary disease (COPD) leading to better strategies for measuring clinical trials outcomes
12. European Medicines Research Training Network
Expected outcome: a European biopharmaceutical research training platform providing a sustainable academia-industry cross-disciplinary approach to efficient organisation of training courses on emerging science and technologies across Europe.
13. Safety sciences for medicines training programme
Expected outcome: training programme integrating all safety-relevant disciplines linking animal and human/patient safety data thereby facilitating a more holistic evaluation of new medicines
14. Pharmaceutical medicine training programme
Expected outcome: establish a network of academic centres that delivers postgraduate training programmes in pharmaceutical medicine including quality management of the processes and outcomes.
15. Pharmacovigilance training programme